Incyte Gets FDA Approval for Rare-Blood-Cancer Treatment

By Dean Seal

Incyte Corp. said Friday that the U.S. Food and Drug Administration has approved its treatment Pemazyre for adults with extremely rare and aggressive blood cancers.

Pemazyre is a fibroblast growth factor receptor inhibitor, and has been approved to treat adults living with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

"These are complex hematologic malignancies with a range of presentations, and this approval highlights Incyte's continued leadership and commitment to advancing care for patients with rare blood cancers," Chief Executive Hervé Hoppenot said.

The approval was based on a Phase 2 study that evaluated the treatment's efficacy in 28 patients.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

August 26, 2022 10:41 ET (14:41 GMT)

Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jun 2024 to Jul 2024